Kayentis, a global provider of eCOA (electronic Clinical Outcome Assessment) and decentralized clinical trial solutions, helps pharma, biotechs, sponsors and CROs bring simplicity, efficiency and quality to the collection of clinical trial data from both patients and sites. Since 2003, Kayentis has been active in clinical development, with a strong specialization in eCOA solutions for phases II/III across a broad range of therapeutic areas. Over the years, it has developed a full range of services and is now enlarging its portfolio beyond eCOA solutions to support the post-COVID new normal of decentralized and hybrid trials. The company has conducted digital data collection for over 260 clinical trials in 79 countries (16,000 sites and 90,000 patients), employing 120 languages. It has offices in the US (Boston), France (Grenoble) and Japan (Tokyo), and currently employs 185 staff. www.kayentis.com